Clinical trials have shown that zanamivir can reduce the duration of influenza symptoms by about one to two days if administered within 48 hours of symptom onset. It is also effective in reducing the severity of symptoms and the rate of complications such as bronchitis and pneumonia. When used prophylactically, zanamivir has been shown to reduce the risk of developing influenza by approximately 70-90%.
